SCHEMBL2277302

SCHEMBL2277302

COCCOc1cccc(/C=C/C(=O)c2c(O)cc(C)n(C)c2=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.48
ABCG2 Q9UNQ0 4/20 0.48
MAOB P27338 7/20 0.44
MAOA P21397 4/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP19A1 P11511 1/20 0.43
NR1H4 Q96RI1 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2D6 P10635 2/20 0.43
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A1 P04798 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2277304 1.00 APP (0.48) APPABCG2MAOBMAOACYP2C9
SCHEMBL2278993 0.91 ABCG2 (0.47) APPABCG2MAOBMAOACYP2C9
SCHEMBL2278989 0.91 ABCG2 (0.47) APPABCG2MAOBMAOACYP2C9
SCHEMBL2284216 0.90 ABCG2 (0.46) APPABCG2MAOBMAOACYP2C9
SCHEMBL2284220 0.90 ABCG2 (0.46) APPABCG2MAOBMAOACYP2C9
SCHEMBL2277045 0.90 ABCG2 (0.46) APPABCG2MAOBMAOACYP2C9
SCHEMBL2277049 0.90 ABCG2 (0.46) APPABCG2MAOBMAOACYP2C9
SCHEMBL2281864 0.88 ABCG2 (0.44) APPABCG2MAOBMAOACYP2C9
SCHEMBL2279845 0.88 BCHE (0.47) APPABCG2MAOBMAOALMNA
SCHEMBL2279849 0.88 BCHE (0.47) APPABCG2MAOBMAOALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 APP 3864/4885ABCG2 4878/4885MAOB 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.